We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


PerkinElmer Launches New AlphaLISA® SureFire® Ultra Assays

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "PerkinElmer Launches New AlphaLISA® SureFire® Ultra Assays"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PerkinElmer, Inc. has announced the launch of its AlphaLISA® SureFire® Ultra™ assays. These solutions are designed to reduce assay time by up to 50 percent and to improve the protein phosphorylation detection process. This is critical for helping life science professionals to obtain more accurate results in biotherapeutic drug discovery research.

With high sensitivity and wide dynamic range to detect protein phosphorylation, even at low levels, AlphaLISA SureFire Ultra assays are quick and easy to run with a minimal amount of sample, significantly reducing time and expense. Researchers can use the assays to analyze cell lysates or tissue lysates, whether they are treated with therapeutic antibodies or small molecules.

“PerkinElmer is committed to developing advanced solutions for screening virtually all types of samples while controlling the quality of therapeutic antibodies,” said Brian Kim, President, Life Sciences & Technology, PerkinElmer. “Providing new assays that help improve the research and quality control process can lead to breakthroughs in the lab and development of new biotherapeutic treatments.”

The AlphaLISA SureFire Ultra assays use TGR BioSciences’ CaptSure™ technology to eliminate antibody interference in the therapeutic antibody screening process. AlphaLISA SureFire Ultra sensitivity and dynamic range also make it ideal for other types of screening, such as small molecule modulation, detection of low and basal levels of phosphorylation, and detection of phosphorylation in tissue lysates.

The assays also leverage PerkinElmer’s AlphaLISA technology that has better spectral characteristics related to hemoglobin interference, which can otherwise hinder the accuracy of measurements. AlphaLISA SureFire Ultra generates results in less than 2½ hours with only one or two incubation steps and no washing. Researchers can analyze different endogenous or transfected targets in parallel - all on the same plate.

AlphaLISA SureFire Ultra assays can be read on Alpha-enabled plate readers such as PerkinElmer’s EnSight™ and EnSpire® Multimode Plate Readers, and PerkinElmer’s EnVision® Multilabel Plate Reader. These assays can also be automated with PerkinElmer’s JANUS® Automated Workstation to enable greater productivity.